Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04429061
Other study ID # IRB-300002251
Secondary ID R01MH116789
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2020
Est. completion date December 31, 2023

Study information

Verified date April 2024
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

"SKILLZ," is a mixed methods evaluation of the Grassroots Soccer (GRS) SKILLZ Package based in Lusaka, Zambia. The package is made up of three football-based programs: (1) SKILLZ-Girl - implemented in schools as part of a 10-week program culminating in a tournament event; (2) SKILLZ-Club - implemented as an ongoing extra-curricular activity after the completion of SKILLZ-Girl; (3) SKILLZ-Plus - a clinic based football group targeted at girls that are HIV-positive. The programs work together to build a continued support system which encourages uptake of Sexual Reproductive Health (SRH) and HIV services, while facilitating ART adherence (for HV-positive participants) and continued engagement with health services over the long-term (whether to contraceptive methods, HIV prevention services, HIV repeat testing, and/or HIV treatment and care). The study team has developed an enhanced SKILLZ-Girl offering, which will include a comprehensive module on HIVST, contraceptives and PrEP, access to a nurse during the implementation of sessions and the additional offering of HIVST and contraceptive services at the event along with ongoing engagement through the SKILLZ-Club program (Enhanced Arm) , The central hypothesis is that this enhanced curriculum will increase HIV testing and contraceptive uptake compared to the standard SKILLZ curriculum & standard event (SOC Arm). The investigators further hypothesize that the intervention in the enhanced arm will positively and directly affect a number of mediating factors including attendance at soccer events where community-based SRH services are offered, SRH knowledge, empowerment, self-confidence, and perceptions of gender balance, and (reduced) stigma. For girls found to be HIV-positive, the follow-on SKILLZ intervention (SKILLZ-Plus) has been designed to facilitate linkage to HIV care and treatment, reduce HIV-related stigma, increase disclosure to family and partners, increase feelings of social support, empowerment, self-efficacy, and ultimately adherence to ARVs, viral load suppression (VLS) and retention in HIV care and treatment. This study will be conducted in up to 32 secondary schools that GRS currently serves in the Lusaka Urban District.


Description:

Research aim(s)/General Objective and Specific Objectives Aim 1: (a) Assess the impact of SKILLZ over two years on HIV testing and (b) SRH-related prevention services uptake among adolescent girls aged 16-19 in up to 23 intervention schools (with enhanced HIVST, PrEP, and contraceptive method offerings) compared to up to 23 control schools using a quasi-experimental difference-in-difference approach; and Aim 1: (b) Describe linkage to care and treatment, and viral load suppression and retention at 6, 12, and 18 months for girls who are identified to be HIV+ during the study, using qualitative, programmatic, and administrative data. This will be achieved by i) using a quasi-experimental difference-in-difference approach that compares girls aged 16 and over in approximately 23 SKILLZ control schools compared to approximately 23 schools where SKILLZ will be delivered with the enhanced HIVST and a variety of contraceptive method offerings; and ii) through a cohort model using pre-existing SmartCare data on HIV+ individuals in care to match to adolescent girls aged 16 and over from the same district (Lusaka) who are identified to be HIV+ at any time during SKILLZ-Girl or SKILLZ-Club participation. Aim 2: Examine how the intervention works including lessons learned for future implementation by 1. conducting a process evaluation to identify mediators, predictors, and barriers to uptake of the SKILLZ-Girl, Club, and Plus curricula both quantitatively through mediation and moderation analyses and qualitatively through a sequential explanatory approach using focus groups discussions, interviews and observation with coaches and girls; and by 2. monitoring fidelity Aim 3: Estimate the short- and long-term cost-effectiveness and return on investment of the SKILLZ Girl, Club, and Plus curricula for improving health outcomes for adolescent girls. This is a mixed-methods evaluation of the SKILLZ intervention using the following approaches: A quasi-experimental cohort of school-aged 16-year-old and over females to be followed for a period of 18 month will be evaluated with a difference-in-difference (DID) approach to estimate HIV testing uptake and sexual/reproductive health services use. Primary and secondary outcomes will be measured at several timepoints longitudinally across up to 23 schools offering the SKILLZ-Girl and SKILLZ-Clubs program and up to 23 schools offering the "standard of care" (SOC) and SOC Clubs. Recruitment is anticipated to take 6 months on a rolling basis. The order in which schools will be selected will be random. Participants will be clustered at the school-level; a random sample of girls will be enrolled from each participating school, aged 16-years at the commencement of SKILLZ-Girl and who are in a grade where GRS is offering the SKILLZ-Girl curriculum All enrolled girls will be followed over the 18 months' time period to assess SRH service uptake, including HIV testing. It is estimated that the majority (~98%) of girls testing for HIV will likely be HIV-negative, based on estimates from programmatic GRS data. While HIV-positive girls will continue to participate in the school-based SKILLZ-Girl and Clubs activities and followed for SRH use, they will also be offered contemporaneous enrolment into SKILLZ-Plus upon infection; retention in care and Viral Load Suppression (VLS) at 6, 12, and 18 months will be measured for this subset. Process evaluation: A process evaluation will be conducted to better understand the casual pathways and effect mediators and moderators using mixed methods approaches, including supplemental qualitative data collection. To investigate reasons why the program components (SKILLZ-Girl, Club & Plus) might fail or succeed in different schools or communities and assess intervention effect mediators and moderators for HIV testing and contraceptive use uptake we will use a mixed methods approach involving: (1) quantitative analyses of baseline survey data for testing how variables can moderate the observed impact of the intervention, and (2) qualitative data collected from a subset of SKILLZ participants in the evaluation cohort and their coaches to further understand potential mediating pathways. Fidelity monitoring: The study includes measures to monitor fidelity of the intervention implementation, including receptivity to and understanding of the intervention amongst participants, the perceived appropriateness and relevancy of the intervention for adolescent girls in school, and the extent to which the intervention was delivered per protocol in different communities and schools. Economic evaluation: Time permitting (given the uncertainty of delays due to COVID), the study will estimate the short- and long-term cost-effectiveness and return on investment of SKILLZ for improving health outcomes for adolescent girls. Data collection plan and tools SmartCare electronic data: All antiretroviral therapy services offered as part of the study will be captured in the National EMR, SmartCare, which permits measuring of utilization and clinical outcomes (i.e., Linkage to Care, VLS) at soccer events, mobile clinics, and public clinics in Lusaka. VLS is defined as below detection, i.e., less than 50 copies/ml. Retention in care will also be measured using SmartCare data on pharmacy visits and defined as accessing pharmacy within a 90-day window of visits. Consent will be requested from all participants as part of the consent process to access their SmartCare records. Youth-Friendly services electronic data: Depending on the location of the school, the girl's residential address and/or her own personal preferences, participants will be referred to either the PEPFAR Funded DREAMS houses or the M.A.C. funded youth-friendly spaces based in local MOH clinics in order to access ongoing SRH services not provided by the coaches in their CBD role (this will include accessing PrEP, STI testing and long-term contraceptive methods). All interactions with the DREAMS houses or M.A.C centres (including meeting with counsellors, referral and uptake of services) are captured in their respective electronic databases. Consent will be requested from all participants as part of the consent process to allow researchers to access either DREAMS or M.A.C data should they chose to access either of these services. Survey at baseline: A baseline survey will be administered to approximately 50 girls per school randomly selected to participate in the evaluation to collect information on school characteristics, sexual behaviour, age, HIV knowledge, maternal education, baseline HIV status, and sexual/reproductive health uptake and retention. These variables will be used as covariates and moderators for service uptake and retention. The target sample of approximately 1380 girls will respond to a survey self-administered using ODk software upon informed consent. The survey will be available in English, Nyanja and Bemba. Coaches and study staff will on site be help girls navigate the survey. If during baseline, it appears that there has been sufficient time to measure change, or the full SKILLZ-Girl curriculum was not administered, the baseline survey may be re-administered to assist with validation of responses (as opposed to implementing the follow-up survey provided below). Survey post-SKILLZ-Girl event, 6-, 12-, and 18 months: A total of approximately 30 girls per school (regardless of HIV status) will respond to a ODK survey to collect information on sexual behaviour, HIV knowledge, maternal education, sexual/reproductive health uptake and retention. Post-SKILLZ-Girl survey data will be used to assess the effect of SKILLS Girl and SKILLZ-Club on the outcomes of interest. In schools selected to offer SKILLZ-Club, surveys will be conducted during club attendance approximately 6 months after the SKILLZ-Girl community soccer event. Surveys will be completed individually by the participant on a secure tablet physically or via phone. Study staff will be available to assist participants to navigate the survey if they request assistance. If a participant has opted to not attend the clubs or has since left or changed schools, the coaches and study staff will attempt to trace participants in the community in order to complete the follow-up survey. Where a participant is contacted for follow-up and it is discovered that she has left Lusaka, Chilanga, Chongwe and Kafue districts and it is not possible for study staff to arrange a visit to meet with her, a personalized survey link will be sent to her via email or WhatsApp (based on the participant's preference). She will then be invited to complete and submit the survey online. Alternatively, if the participant prefers study staff will complete the survey with the participant over the phone and enter their responses directly into ODK. In the schools selected not to offer SKILLZ-Club, GRS will arrange for a 2-hour meeting session with all participants still enrolled at that school, where all participants will complete the surveys. If a participant opts to not attend the meeting or has since left or changed schools, the coaches and study staff will attempt to trace participants in the community in order to complete the follow-up survey. Data management and storage Quantitative: Individual-level data will be collected on clinical, laboratory, and demographic characteristics, including retention in care and VLS at 6, 12 and 24 months. Using case reporting forms (CRFs), the team will collect study-specific data, including information obtained directly from participants, routine programmatic data from GRS and abstract routine clinical data from paper-based medical records, the SmartCare Electronic Management Records (EMR), CIDRZ Laboratory Information Management System (LIMS) and DREAMS electronic management system. Routinely collected individual-level clinical data are first written onto forms in the paper medical record and then entered into the SmartCare EMR. SmartCare serves as a repository of clinical data for HIV-infected individuals and includes such data fields as: ART initiation date, ART regimen, visit dates, and laboratory data. GRS will collect programmatic data through a combination of paper and electronic data entry via tablets, with all data stored securely in RedCap. Where paper files are used for programmatic management, data will be manually entered by study staff directly into the RedCap database. De-identified data will made available to GRS co-investigators to enable review of key fidelity and quality indicators in order to monitor implementation in real time. All paper study files will be stored in secured, locked cabinets located in locked rooms available to study staff only. A secure server will be used to store encrypted study data, including the study database. All personal identifiers will be removed prior to generating the analytical dataset. Qualitative: All data will be obtained using digital audio recorders. Recorded data will be transferred on to a lockable computer kept by the co-principal investigator leading the qualitative research. Transcripts will go through a QA/QC process where researchers will cross check randomly selected transcribed verbatim with the recordings. Data analysis plan The primary outcome is the probability of testing for HIV at any time during the period when SKILLZ is delivered through to 24 months after the final soccer event. The primary analysis for Aim 1 will follow a difference-in-difference (DID) effect between study arms. The outcome of interest will be regressed on an indicator of study arm assignment interacted with a dichotomous variable POST which indicates the outcome after the intervention is implemented; this differentiates baseline and end-line for each study arm, controls for any time dependent variables that might confound the effect, as well as any time-invariant observed or unobserved confounders that might differ between study arm schools. Clustering by school will be accounted for by a generalized estimating equation approach. Intention-to-treat (ITT) will be evaluated by including all girls in the evaluation cohort assigned to each arm rather than all girls who actually participated in SKILLZ.


Recruitment information / eligibility

Status Completed
Enrollment 2153
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria: - The student is >16 years of age prior to the first session of SKILLZ-Girl or the student will turn 16 years of age before the last session of SKILLZ-Girl (ie prior to the event) - Is enrolled in one of the SKILLZ STUDY schools - Is able to converse in and comprehend either Nyanja, English and/or Bemba - The Parent/Guardian of the participant has consented for the participant to take part in the study Exclusion Criteria: - The student has a mental disability that would interfere with their ability to give informed consent

Study Design


Intervention

Behavioral:
SKILLZ-Girl curriculum
Participation in the SKILLZ-Girl curriculum and SKILLZ-Club

Locations

Country Name City State
Zambia Centre of Infectious Disease Research Zambia Lusaka

Sponsors (6)

Lead Sponsor Collaborator
University of Alabama at Birmingham Centre for Infectious Disease Research in Zambia, Grassroot Soccer (GRS), National Institute of Mental Health (NIMH), University of California, San Francisco, Washington University School of Medicine

Country where clinical trial is conducted

Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Undergoing HIV Testing Within 12 Months Number of participants, enrolled in the study, undergoing HIV testing (HIVST our Determine tests) over 1 year. Collected from facility testing registers and community testing registers. 12 months
Primary Number of Participants Accessing Sexual and Reproductive Health Related Prevention Services Within 12 Months Number of participants, enrolled in the study, accessing contraception, pre-exposure prophylaxis or post exposure prophylaxis over 1 year. Determined through the electronic medical record and clinic registers. 12 months
Primary The Percentage of HIV Infected Participants Being Virally Suppressed at 12 Months The percentage of participants, testing HIV positive, who have an undetectable viral load (as defined by the laboratory doing the test) after one year on treatment. Collected from routine laboratory data. 12 months
Primary The Percentage of HIV Infected Participants Retained in Care at 3 Months The percentage of participants, testing HIV positive, who are actively retained in care at 3 months ie are not more than 7 days late for a scheduled appointment. Determined using the electronic medical record. 3 months
Primary The Percentage of HIV Infected Participants Retained in Care at 6 Months The percentage of participants, testing HIV positive, that have made their scheduled visit to the clinic within the first at 6 months of enrolment. (less than 7 days late), using the electronic medical record. 6 months
Primary The Percentage of HIV Infected Participants Retained in Care at 12 Months The percentage of participants, testing HIV positive, who attend their scheduled visits within the first 12 months of enrolment (less than seven days late). determined through the electronic medical record. 12 months
Secondary Identify Barriers That Prevent Intervention Participation Record and track key barriers through review of routine program data that prevent participants from engaging with the intervention. ie through review of the data collected by coaches from feedback from participants, FGD's and IDI's. During this COVID-19 period, we may be limited or may need to revise our anticipated collection of study results. The study record will reflect these changes as we navigate through the course of the study. Baseline through 12 months
Secondary Fidelity Monitoring or Adherence to the Program as Measured by the Number of Coaching Sessions Conducted Per Plan. Each session that is conducted will be documented including number of participants in attendance (assessed voia attendance registers and routine program data). Baseline through 12 months
Secondary Average Short-term Costs for the Program Implementation Based on Net-costs for the Intervention. Costs will include the personnel to manage the intervention, financial incentives and other related miscellaneous costs. These will be collected by the program manager and study team and will be based on actual costs. Baseline through 12 months
Secondary Conduct a Process Evaluation to Describe How the Intervention Worked FGD's, IDI's and routine program data ( attendance registers, process data and documented observations) will be used to identify mediators, predictors, and barriers to uptake of the SKILLZ package after implementation 12 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2